BriaCell Therapeutics Corp.
BCT.TOTSXHealthcare● Active
$4.34
+$0.03(+0.70%)
Market Cap$8175436
P/E Ratio—
52W High$49
52W Low$4.13
BriaCell Therapeutics Corp. (BCT.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BCT.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 10, 2026EPS Actual
-$3.52
Est. -$4.84 · +27.2%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 10, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
BCT.TO reports quarterly as a TSX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 10, 2026 | -$4.84 | -$3.52 | +27.2% | — | — | — |
| — Q4 FY2025 | Dec 15, 2025 | — | -$8.46 | — | — | — | — |
| — Q4 FY2025 | Oct 16, 2025 | — | -$13.37 | — | — | — | — |
| ▲ Q2 FY2025 | Jun 16, 2025 | -$1.76 | -$1.64 | +6.8% | — | — | — |
| ▼ Q1 FY2025 | Mar 12, 2025 | -$1.94 | -$2.33 | -20.1% | — | — | — |
| ▲ Q4 FY2024 | Dec 12, 2024 | -$0.42 | -$0.22 | +47.6% | — | — | — |
| ▲ Q4 FY2024 | Oct 28, 2024 | -$0.52 | -$0.07 | +86.5% | — | — | — |
| ▲ Q2 FY2024 | Jun 14, 2024 | -$0.55 | $0.11 | +120.0% | — | — | — |
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$3.52
EPS Est.
-$4.84
EPS Surpr.
+27.2%
Revenue
—
Q4 FY2025
Dec 15, 2025
EPS Actual
-$8.46
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Oct 16, 2025
EPS Actual
-$13.37
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Jun 16, 2025Beat
EPS Actual
-$1.64
EPS Est.
-$1.76
EPS Surpr.
+6.8%
Revenue
—
Q1 FY2025
Mar 12, 2025Miss
EPS Actual
-$2.33
EPS Est.
-$1.94
EPS Surpr.
-20.1%
Revenue
—
Q4 FY2024
Dec 12, 2024Beat
EPS Actual
-$0.22
EPS Est.
-$0.42
EPS Surpr.
+47.6%
Revenue
—
Q4 FY2024
Oct 28, 2024Beat
EPS Actual
-$0.07
EPS Est.
-$0.52
EPS Surpr.
+86.5%
Revenue
—
Q2 FY2024
Jun 14, 2024Beat
EPS Actual
$0.11
EPS Est.
-$0.55
EPS Surpr.
+120.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $-3.54 | $-3.54 | $-3.54 | 1 |
| Q4 FY2025 | $-2.34 | $-2.34 | $-2.34 | 1 |
| Q3 FY2025 | $-8.79 | $-8.79 | $-8.79 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 10, 2026 | +27.2% | $5.07 | $5.09 | +0.39% |
| — Q4 FY2025 | Dec 15, 2025 | — | $13.44 | $12.40 | -7.74% |
| — Q4 FY2025 | Oct 16, 2025 | — | $16.50 | $17.19 | +4.18% |
| ▲ Q2 FY2025 | Jun 16, 2025 | +6.8% | $42.20 | $43.00 | +1.90% |
| ▼ Q1 FY2025 | Mar 12, 2025 | -20.1% | $53.20 | $51.00 | -4.14% |
| ▲ Q4 FY2024 | Dec 12, 2024 | +47.6% | $238.50 | $142.50 | -40.25% |
| ▲ Q4 FY2024 | Oct 28, 2024 | +86.5% | $180.00 | $181.50 | +0.83% |
| ▲ Q2 FY2024 | Jun 14, 2024 | +120.0% | $276.00 | $283.50 | +2.72% |
Q1 FY2026+0.39%
Report Date
Mar 10, 2026
EPS Beat/Miss
+27.2%
Price Before
$5.07
Price After
$5.09
Q4 FY2025-7.74%
Report Date
Dec 15, 2025
EPS Beat/Miss
—
Price Before
$13.44
Price After
$12.40
Q4 FY2025+4.18%
Report Date
Oct 16, 2025
EPS Beat/Miss
—
Price Before
$16.50
Price After
$17.19
Q2 FY2025+1.90%
Report Date
Jun 16, 2025
EPS Beat/Miss
+6.8%
Price Before
$42.20
Price After
$43.00
Q1 FY2025-4.14%
Report Date
Mar 12, 2025
EPS Beat/Miss
-20.1%
Price Before
$53.20
Price After
$51.00
Q4 FY2024-40.25%
Report Date
Dec 12, 2024
EPS Beat/Miss
+47.6%
Price Before
$238.50
Price After
$142.50
Q4 FY2024+0.83%
Report Date
Oct 28, 2024
EPS Beat/Miss
+86.5%
Price Before
$180.00
Price After
$181.50
Q2 FY2024+2.72%
Report Date
Jun 14, 2024
EPS Beat/Miss
+120.0%
Price Before
$276.00
Price After
$283.50
Avg Beat Reaction-6.88%
Avg Miss Reaction-4.14%
Beat Rate5 / 8 quarters
Largest Move-40.25% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BCT.TO ends December
BriaCell Therapeutics Corp. (BCT.TO) most recently reported earnings on March 10, 2026 for Q1 FY2026, posting EPS of $-3.52 — beating the analyst consensus of $-4.84 by +27.2%. BCT.TO has beaten EPS estimates for 2 consecutive quarters. The next BCT.TO earnings date is expected around September 1, 2026.
Each quarter, investors track BCT.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCT.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BCT.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BCT.TO earnings · 5 questionsBriaCell Therapeutics Corp.'s next earnings report is expected around September 1, 2026. BCT.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCT.TO historically reports after market close (AMC).
BCT.TO earnings datewhen is BCT.TO earningsBCT.TO next earnings datewhen does BCT.TO report earningsBCT.TO earnings calendar
▸ Source: FMP · BriaCell Therapeutics Corp. SEC filings · US GAAP · BriaCell Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026